CON critic’s recent courtroom setback still has positive signs
A judge has offered Dr. Jay Singleton some reasons for optimism, even as his lawsuit challenging North Carolina's certificate-of-need law…
Close
About Author
Mitch Kokai is senior political analyst for the John Locke Foundation. He joined JLF in December 2005 as director of communications. That followed more than four years as chief state government reporter for News 14 Carolina, now known as Spectrum News. The job included extensive coverage of the General Assembly for the 24-hour local regional television news channel.
Before News 14 Carolina, Kokai worked as a radio news reporter for seven years. He started a radio news department at WENC-AM in Whiteville, then led Chapel Hill’s award-winning radio news team at WCHL-AM. He spent two-and-one-half years as news director and assignment editor for Raleigh’s WPTF-AM.
Mitch is a Columbus, Ohio, native, and a University of North Carolina at Chapel Hill graduate. He has lived in North Carolina since 1989.
Content featuring Mitch Kokai
Locke’s Mitch Kokai discusses Senate slowdown for Biden’s agenda
Mitch Kokai, John Locke Foundation senior political analyst, discusses the U.S. Senate’s sluggish response to President Biden’s agenda. Kokai offered…
Chief justice highlights right of petition in unanimous N.C. Supreme Court ruling
The N.C. Supreme Court has thrown out a lawsuit against owners of an Orange County quarry. Chief Justice Paul Newby’s…
User-fee principle should guide future N.C. transportation choices
A national expert offers five reasons to rely on fees to guide N.C. Department of Transportation decisions.
Locke’s Mitch Kokai analyzes Donald Trump’s U.S. Senate endorsement of Ted Budd
Mitch Kokai, John Locke Foundation senior political analyst, discusses former President Donald Trump’s endorsement of U.S. Rep. Ted Budd in…
Locke’s Mitch Kokai discusses Democrats’ attack on Big Pharma
Mitch Kokai, John Locke Foundation senior political analyst, discusses U.S. House Democrats’ plan to force companies to lower drug prices.